856 INBRX-106: a novel hexavalent anti-OX40 agonist for the treatment of solid tumors

by Quinn Deveraux, Heather Kinkead, Kyle Jones, Bryan Becklund, Florian Sulzmaier, John Timmer, Brendan Eckelman, Analeah Heidt, William Crago, Emily Rowell, Elisabeth Torretti
Published 2021-11-01

12 Key pharmacokinetic and pharmacodynamic parameters that correlate with the anti-tumor activity of a bispecific PD-L1 conditional 4–1BB agonist

by Quinn Deveraux, Heather Kinkead, Chelsie Macedo, Angelica Sanabria, Garrett Cyprus, Rajay Pandit, James Kalabus, Bryan Becklund, Florian Sulzmaier, John Timmer, Brendan Eckelman, Analeah Heidt
Published 2021-11-01

722 INBRX-121 is an NKp46-targeted detuned IL-2 with antitumor activity as a monotherapy or in combination with multiple cancer immunotherapy modalities

by Heather Kinkead, Chelsie Macedo, Angelica Sanabria, Rajay Pandit, Florian Sulzmaier, John Timmer, Brendan Eckelman, Analeah Heidt, Anya Polovina, Nadja Kern, Abrahim Hussain, Sae Jeong Ahn, William Crago
Published 2021-11-01